Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines

Molecular and Cellular Endocrinology

Volumn 198, Issue 1-2, 2002, Pages 105-114

  Orio Jr , Francesco ^a,b,c   Térouanne, Béatrice ^a   Georget, Virginie ^a   Lumbroso, Serge ^a,b   Avances, Christophe ^a,d   Siatka, Christian ^a   Sultan, Charles ^a,b  

^a INSERM   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Hopital Gaston Doumergue   (France)

Author keywords

Androgen receptor; DU 145; EGF; IGF 1; Normal prostate epithelial cells; PNT1A; Prostate cancer cells

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; HYBRID PROTEIN; HYDROXYFLUTAMIDE; IODINE 125; LUCIFERASE; SOMATOMEDIN C;

BINDING ASSAY; CANCER CELL CULTURE; CELL LEVEL; CELL NUCLEUS TRANSPLANTATION; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; EXPRESSION VECTOR; GENE ACTIVATION; GENETIC TRANSFECTION; HORMONE DETERMINATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE MAMMARY TUMOR ONCOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL LINE; EPIDERMAL GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS);

EID: 0037203497     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00374-X     Document Type: Conference Paper

References (38)

1. Avances C., Georget V., Terouanne B., Orio F., Cussenot O., Mottet N., Costa P., Sultan C. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. Mol. Cell. Endocrinol. 184:2001;13-24.
2. Berthon P., Waller A.S., Villette J.M., Loridon L., Cussenot O., Maitland N.J. Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int. J. Cancer. 73:1997;910-916.
3. Bubulya A., Wise S.C., Shen X.Q., Burmeister L.A., Shemshedini L. C-jun can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271:1996;24583-24589.
4. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
5. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:1998;563-566.
6. Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5:1999;280-285.
7. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
8. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Hittmair A., Zhang J., Thurnher M., Bartsch G., Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate. 28:1996;392-405.
9. Cussenot O., Berthon P., Berger R., Mowszowicz I., Faille A., Hojman F., Teillac P., Le Duc A., Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J. Urol. 146:1991;881-886.
10. DiGiovanni J., Kiguchi K., Frijhoff A., Wilker E., Bol D.K., Beltran L., Moats S., Ramirez A., Jorcano J., Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. USA. 97:2000;3455-3460.
11. Dotzlaw H., Moehren U., Mink S., Cato A.C., Iniguez Lluhi J.A., Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 16:2002;661-673.
12. Fiorelli G., De Bellis A., Longo A., Giannini S., Natali A., Costantini A., Vannelli G.B., Serio M. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab. 72:1991;740-746.
13. Gehm B.D., McAndrews J.M., Jordan V.C., Jameson J.L. EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway. Mol. Cell. Endocrinol. 159:2000;53-62.
14. Georget V., Lobaccaro J.M., Terouanne B., Mangeat P., Nicolas J.C., Sultan C. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol. Cell. Endocrinol. 129:1997;17-26.
15. Gupta C. Modulation of androgen receptor (AR)-mediated transcriptional activity by EGF in the developing mouse reproductive tract primary cells. Mol. Cell. Endocrinol. 152:1999;169-178.
16. Hall J.A., Harris M.A., Intres R., Harris S.E. Acidic fibroblast growth factor gene 5′ non-coding exon and flanking region from hamster DDT1 cells: identification of the promoter region and transcriptional regulation by testosterone and an FGF protein. J. Cell. Biochem. 51:1993;116-127.
17. Ignar-Trowbridge D.M., Pimentel M., Parker M.G., McLachlan J.A., Korach K.S. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology. 137:1996;1735-1744.
18. Iwamura M., Sluss P.M., Casamento J.B., Cockett A.T. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 22:1993;243-252.
19. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
20. Klotz D.M., Curtis Hewitt S., Ciana P., Raviscioni M., Lindzey J.K., Foley J., Maggi A., DiAugustine R.P., Korach K.S. Requirement of estrogen receptor-{alpha} in insulin-like growth factor-1-induced uterine responses and in vivo evidence for insulin-like growth factor-1/estrogen receptor cross-talk. J. Biol. Chem. 21:2001;21.
21. Lobaccaro J.M., Poujol N., Terouanne B., Georget V., Fabre S., Lumbroso S., Sultan C. Transcriptional interferences between normal or mutant androgen receptors and the activator protein 1 - dissection of the androgen receptor functional domains. Endocrinology. 140:1999;350-357.
22. MacDonald A., Habib F.K. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer. 65:1992;177-182.
23. Marelli M.M., Moretti R.M., Dondi D., Motta M., Limonta P. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology. 140:1999;329-334.
24. Martin M.B., Franke T.F., Stoica G.E., Chambon P., Katzenellenbogen B.S., Stoica B.A., McLemore M.S., Olivo S.E., Stoica A. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology. 141:2000;4503-4511.
25. McEwan I.J., Gustafsson J. Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc. Natl. Acad. Sci. USA. 94:1997;8485-8490.
26. Moretti R.M., Marelli M.M., Dondi D., Poletti A., Martini L., Motta M., Limonta P. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J. Clin. Endocrinol. Metab. 81:1996;3930-3937.
27. Oettgen P., Finger E., Sun Z., Akbarali Y., Thamrongsak U., Boltax J., Grall F., Dube A., Weiss A., Brown L., Quinn G., Kas K., Endress G., Kunsch C., Libermann T.A. PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. Chem. 275:2000;1216-1225.
28. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., Gorman C.M., Parker M.G., Sliwkowski M.X., Slamon D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446.
29. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
30. Putz T., Culig Z., Eder I.E., Nessler-Menardi C., Bartsch G., Grunicke H., Uberall F., Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 59:1999;227-233.
31. Reinikainen P., Palvimo J.J., Janne O.A. Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology. 137:1996;4351-4357.
32. Schuurmans A.L., Bolt J., Veldscholte J., Mulder E. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J. Steroid Biochem. Mol. Biol. 40:1991;193-197.
33. Smith C.L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58:1998;627-632.
34. Tyagi R.K., Lavrovsky Y., Ahn S.C., Song C.S., Chatterjee B., Roy A.K. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 14:2000;1162-1174.
35. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by IL-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 19:2001;19.
36. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60:2000;6841-6845.
37. Wilding G., Zugmeier G., Knabbe C., Flanders K., Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol. Cell. Endocrinol. 62:1989;79-87.
38. Yan G., Fukabori Y., Nikolaropoulos S., Wang F., McKeehan W.L. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol. Endocrinol. 6:1992;2123-2128.